A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.
Phase of Trial: Phase I/II
Latest Information Update: 20 May 2015
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Inborn urea cycle disorders; Liver dysfunction
- Focus Adverse reactions; First in man
- Sponsors Promethera Biosciences
- 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Feb 2014 New trial record